VIA
IGMS

Vident Investment Advisory’s IGM Biosciences IGMS Stock Holding History

Vident Investment Advisory’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-38,078
Closed -$523K – 1257
2023
Q1 		$523K Sell
38,078
-1,405
-4% -$29.1K 0.02% 764
2022
Q4 		$672K Sell
39,483
-4,726
-11% -$94.5K 0.03% 612
2022
Q3 		$1M Sell
44,209
-4,737
-10% -$95.7K 0.03% 592
2022
Q2 		$882K Buy
+48,946
New +$872K 0.03% 662
2021
Q4 		– Sell
-15,603
Closed -$1.03M – 1217
2021
Q3 		$1.03M Sell
15,603
-1,114
-7% -$85.2K 0.03% 667
2021
Q2 		$1.39M Sell
16,717
-407
-2% -$30.2K 0.04% 554
2021
Q1 		$1.31M Sell
17,124
-70
-0.4% -$6.37K 0.04% 537
2020
Q4 		$1.52M Sell
17,194
-3,354
-16% -$236K 0.06% 399
2020
Q3 		$1.52M Sell
20,548
-1,452
-7% -$85.9K 0.08% 358
2020
Q2 		$1.61M Buy
+22,000
New +$1.34M 0.08% 280

Other funds holding IGMS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vident Investment Advisory's IGMS Position: Q2 2023 in Review

Vident Investment Advisory sold out of IGM Biosciences (IGMS) in Q2 2023, closing a stake of 38,078 shares — an estimated $523K sold.

Vident Investment Advisory first reported a position in IGMS in Q2 2020 and held it in 10 quarters. The position peaked at $1.61M in Q2 2020. 79 funds tracked by Wall St. Rank hold IGMS as of Q2 2023.

  • Vident Investment Advisory reported no remaining IGM Biosciences position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 38,078 IGM Biosciences shares in Q2 2023, an estimated $523K.
  • Vident Investment Advisory first reported a position in IGM Biosciences in Q2 2020 and held it in 10 quarters.
  • Vident Investment Advisory's IGM Biosciences position peaked at $1.61M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.